299 related articles for article (PubMed ID: 33315135)
1. [Precision oncology : How can high-quality healthcare remain affordable for all in the face of diagnostic and therapeutic costs?].
Schlomm T; Rödiger T; Graalmann J
Urologe A; 2021 Jan; 60(1):3-7. PubMed ID: 33315135
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers: a paradigm shift towards personalized cancer medicine.
La Thangue NB; Kerr DJ
Nat Rev Clin Oncol; 2011 Aug; 8(10):587-96. PubMed ID: 21862978
[TBL] [Abstract][Full Text] [Related]
3. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
Gupta S; Smith TR; Broekman ML
J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
[TBL] [Abstract][Full Text] [Related]
4. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
5. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
6. [Personalized medicine in oncology].
Lörsch AM; Jung J; Lange S; Pfarr N; Mogler C; Illert AL
Pathologie (Heidelb); 2024 May; 45(3):180-189. PubMed ID: 38568256
[TBL] [Abstract][Full Text] [Related]
7. Future Approaches to Precision Oncology-Based Clinical Trials.
Mittra A; Moscow JA
Cancer J; 2019; 25(4):300-304. PubMed ID: 31335395
[TBL] [Abstract][Full Text] [Related]
8. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.
Normanno N; Apostolidis K; de Lorenzo F; Beer PA; Henderson R; Sullivan R; Biankin AV; Horgan D; Lawler M
Semin Cancer Biol; 2022 Sep; 84():293-301. PubMed ID: 34389490
[TBL] [Abstract][Full Text] [Related]
9. [Molecular tumor diagnostics as the driving force behind precision oncology].
Kazdal D; Menzel M; Budczies J; Stenzinger A
Dtsch Med Wochenschr; 2023 Sep; 148(18):1157-1165. PubMed ID: 37657453
[TBL] [Abstract][Full Text] [Related]
10. Precision diagnostics: integration of tissue pathology and genomics in cancer.
Sharma S; George P; Waddell N
Pathology; 2021 Dec; 53(7):809-817. PubMed ID: 34635323
[TBL] [Abstract][Full Text] [Related]
11. [Agnostics of immunological therapies in monotherapy and in association: impacts on clinical governance and on the patient's journey.].
Marchetti P
Recenti Prog Med; 2021 Dec; 112(12):811-815. PubMed ID: 34924578
[TBL] [Abstract][Full Text] [Related]
12. Enabling Precision Oncology Through Precision Diagnostics.
Brown NA; Elenitoba-Johnson KSJ
Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine in oncology: New practice models and roles for oncology pharmacists.
Walko C; Kiel PJ; Kolesar J
Am J Health Syst Pharm; 2016 Dec; 73(23):1935-1942. PubMed ID: 27864201
[TBL] [Abstract][Full Text] [Related]
14. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
15. Redefining "Medical Care.".
Roth LR
Cornell J Law Public Policy; 2017; 27(1):65-106. PubMed ID: 29239587
[TBL] [Abstract][Full Text] [Related]
16. Precision Oncology in Canada: Converting Vision to Reality with Lessons from International Programs.
Liu G; Cheung WY; Feilotter H; Manthorne J; Stockley T; Yeung M; Renouf DJ
Curr Oncol; 2022 Sep; 29(10):7257-7271. PubMed ID: 36290849
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.
Miller AM; Omenn GS; Kean MA
Clin Cancer Res; 2016 May; 22(10):2335-41. PubMed ID: 27087022
[TBL] [Abstract][Full Text] [Related]
18. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
19. Challenging Standard-of-Care Paradigms in the Precision Oncology Era.
Subbiah V; Kurzrock R
Trends Cancer; 2018 Feb; 4(2):101-109. PubMed ID: 29458960
[TBL] [Abstract][Full Text] [Related]
20. Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?
Morgan G; Aftimos P; Awada A
Curr Opin Oncol; 2016 Sep; 28(5):441-6. PubMed ID: 27428363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
